FDA engages with stakeholders to collaboratively secure the U.S. drug supply chain. The Partnership for DSCSA Governance (PDG) is an independent, sector-neutral, non-profit organization working to support effective and efficient implementation of the DSCSA requirements for electronic, interoperable tracing and verification of prescription drugs in the U.S. PDG membership includes a range of supply chain stakeholders including trading partners, trade or professional associations, technical experts and other stakeholders.
FDA participates on the PDG interoperable committee which fosters critical discussions about technical challenges or operational issues faced by trading partners and other stakeholders. These collaborative efforts support implementation of the enhanced drug distribution security requirements which will go into effect November 27, 2023 for tracing products at the package level.
These collaborative efforts help improve the integrity of the drug supply by enhancing the FDA’s ability to:
- Prevent harmful drugs from entering the supply chain.
- Detect and identify harmful drugs before they enter the supply chain or once they are in distribution.
- Respond rapidly and effectively when harmful drugs are found.